hs-CRP vs CRP: Same Protein, Different Assay Range
There is one analyte. C-reactive protein is a pentameric acute-phase protein made in the liver, and both tests measure it. The difference is assay sensitivity: a standard CRP method typically reports down to about 3–5 mg/L and is designed to quantify the tens-to-hundreds range seen in infection and active inflammation, while a high-sensitivity method resolves reliably down to roughly 0.1–0.3 mg/L. If you want to know whether your baseline sits at 0.4 or 2.1 mg/L, order hs-CRP. If you want to know whether an acute process is driving CRP to 80 mg/L, either assay answers it, and the standard one is cheaper. The naming convention is a historical artifact of instrument capability rather than a distinction in what is being measured.1
What “high-sensitivity” means at the bench
Both assay families are immunoturbidimetric or immunonephelometric. Anti-CRP antibodies bound to latex microparticles agglutinate in the presence of CRP, and the instrument measures light scatter or absorbance change. The hs-CRP version uses higher-affinity antibody preparations, larger or more uniform latex particles, and a calibration curve anchored at the low end. That yields a limit of quantitation around 0.1–0.2 mg/L with a coefficient of variation under 10%, against a standard assay that may have a CV of 20% or worse near 1 mg/L.
Modern analyzers have blurred the line. Many contemporary “standard” CRP applications on high-throughput chemistry platforms now have functional sensitivity in the 0.3–1 mg/L range, which is adequate for risk categorization. A 2022 comparison found that routine laboratory CRP values in the lower range correlate closely with hs-CRP results, to the point that the routine assay can substitute for the costlier one in many settings. The practical consequence is that you should read your report’s stated lower reporting limit rather than trust the label. If the report says “<5 mg/L” or “<3 mg/L”, the number is useless for risk stratification no matter what the test is called.
Reference standardization helps here. Both assay types are calibrated against the same certified reference material, so a 2.0 mg/L result from a well-calibrated standard assay and a 2.0 mg/L hs-CRP result mean the same thing.1 Units are the other trap. Many labs report CRP in mg/dL and hs-CRP in mg/L, and 0.3 mg/dL is 3 mg/L. Check your units before you compare results across labs or across years.
The conversion question
People ask whether CRP can be converted to hs-CRP. Within the measurable range of both assays, no conversion is needed, because the assays are quantifying the same protein against the same standard. The problem is one-directional censoring. A standard result of “<5 mg/L” cannot be converted to a point estimate, because the true value could be 0.3 or 4.8, and those imply different things about your baseline.
Where conversion has been studied formally, it is for the reverse direction. Work in periprosthetic joint infection derived a linear relationship between high- and low-sensitivity CRP to let clinicians apply thresholds developed on one assay to results from the other.2 That is a calibration exercise for a specific clinical cutoff. It does not recover precision the original assay never had. Our view: if the number matters to you, order the sensitive assay and skip the arithmetic.
When the low range carries information
The reason anyone cares about resolving 0.5 from 2.5 mg/L is cardiovascular epidemiology. hs-CRP in the low single digits is an independent predictor of future vascular events, and the conventional risk tiers are under 1 mg/L for low, 1 to 3 for average, and above 3 for high.3 These cutoffs came out of large prospective cohorts, and they are population risk strata rather than a diagnosis of anything. A value above 10 mg/L is usually treated as an acute-phase signal and not interpreted as a chronic risk marker at all. The standard advice is to repeat in two to three weeks after any intercurrent illness resolves.
hs-CRP also tracks with other metabolic markers. A cross-sectional study in cardiovascular disease patients reported higher hs-CRP levels in those with elevated LDL cholesterol.4 A prospective cohort in middle-aged and older Chinese adults examined two-point changes in LDL-C and hs-CRP together and related those trajectories to major adverse cardiovascular events.5 The pattern that emerges is that a single draw is weak evidence and repeated draws over years are much stronger. That is a good argument for keeping your own time series.
The proinflammatory phenotype work is worth understanding if you plan to interpret your own numbers. Individuals with persistently elevated hs-CRP show corresponding changes in other inflammatory readouts, which is part of why the marker carries prognostic weight rather than merely tracking noise.6 In chronic kidney disease, CRP alongside albumin, interleukin-6, and fetuin-A predicts mortality and cardiovascular outcomes, which illustrates how the marker behaves in populations with sustained inflammatory burden.7
Where the standard assay is the right tool
High-sensitivity resolution buys nothing when concentrations are high. In suspected bacterial infection, CRP commonly runs from tens to hundreds of mg/L, and the clinically relevant discrimination happens well above the standard assay’s detection floor. Neonatal sepsis screening is a clear case. Studies evaluating CRP, hs-CRP, and interleukin-6 as early markers find the sensitive assay adds little over the conventional one. The reason is that the signal of interest is far from the low-end boundary.8 Broader biomarker validity work in neonatal sepsis points the same way.9
The same logic applies to monitoring inflammatory conditions, post-operative courses, and treatment response in rheumatology. What you want is a trajectory across a wide dynamic range, and the standard assay covers that at lower cost. Use hs-CRP when your expected values are under 10 mg/L and you need to distinguish within that band.
How we would set this up for a personal baseline
Order hs-CRP, always, and treat it as one channel in a longitudinal series rather than a single verdict. Draw at least twice, two to four weeks apart. Each draw should come with no acute illness, no vaccination in the prior week, and no strenuous exercise in the prior 48 hours. Within-person biological variation in CRP is substantial, so a single value can mislead by a factor of two. Take the median of your draws as your baseline.
Keep the raw values and the units in whatever store you use. Record the assay method, the instrument, and the lab’s stated limit of quantitation as well. A three-column CSV of date, value in mg/L, and assay lower limit is enough to make later results comparable. Flag and set aside any value above 10 mg/L, and record what was happening that week. Those points are real but they belong to a different process than your chronic baseline.
Pair hs-CRP with markers that move on different timescales. Interleukin-6 sits upstream of hepatic CRP production and responds faster. Ferritin, fibrinogen, and albumin round out the acute-phase picture. Albumin in particular moves in the opposite direction during sustained inflammation.7 Interpretation of any persistently elevated result belongs with a clinician, because the differential is wide and includes conditions that need workup rather than tracking.
Questions people also ask
Can you convert CRP to hs-CRP? Not from a censored result. If your standard assay reports “<5 mg/L”, the information needed to place you in a low-single-digit band was never captured. Where both assays return numbers in the same range, the values are already comparable because both are calibrated to the same reference material.1 Formal conversion equations exist for specific clinical thresholds, such as in periprosthetic joint infection.2
Is hs-CRP better than CRP? It is better at the low end and identical everywhere else. For cardiovascular risk stratification the sensitive assay is required, because the cutoffs of 1 and 3 mg/L fall below many standard assays’ reporting limits.3 For suspected infection the standard assay is adequate and cheaper.8
When should you have a CRP or hs-CRP test done? hs-CRP is appropriate as part of a periodic baseline panel when you are well, ideally repeated so you can average out biological variation. Standard CRP is appropriate when an acute or active inflammatory process is suspected and a clinician is directing the workup. Avoid drawing either during or shortly after an infection if your goal is a chronic baseline.
What cancers have high hs-CRP? Elevated CRP appears across many malignancies as a nonspecific consequence of tumor-associated inflammation, and it is not a screening test for any of them. Inflammatory markers including hs-CRP have been studied alongside tumor markers in gynecological conditions such as endometriosis, where they contribute to characterization rather than diagnosis.10 A persistently raised hs-CRP without an obvious cause is a reason to see a clinician. It is not a reason to self-interpret.
Footnotes
-
Anna Wolska, Alan T Remaley. CRP and High-Sensitivity CRP: “What’s in a Name?”. The Journal of Applied Laboratory Medicine, 2022. https://doi.org/10.1093/jalm/jfac076 ↩ ↩2 ↩3
-
Michael T. Milone, Atul F. Kamath, Craig L. Israelite. Converting Between High- and Low-Sensitivity C-Reactive Protein in the Assessment of Periprosthetic Joint Infection. The Journal of Arthroplasty, 2014. https://doi.org/10.1016/j.arth.2013.09.015 ↩ ↩2
-
Sotirios Tsimikas, James T. Willerson, Paul M. Ridker. C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. Journal of the American College of Cardiology, 2006. https://doi.org/10.1016/j.jacc.2005.10.066 ↩ ↩2
-
Meryem Mehmood, Dr. Gulzar Alam, Khunsha Anosh Ali, et al. ELEVATED LDL-C IS ASSOCIATED WITH INCREASED HS CRP LEVELS IN PATIENTS WITH CARDIOVASCULAR DISEASE: A CROSS-SECTIONAL STUDY. Genetics and Molecular Research, 2026. https://doi.org/10.4238/khyjnh35 ↩
-
Jiayin Guo, Bin Zhao, Zongwei Liu, et al. Two‐Point Change Patterns of LDL‐Cholesterol and hs‐CRP and Risk of Major Adverse Cardiovascular Events in Middle‐Aged and Older Chinese Adults: A Prospective Cohort Study. Health Science Reports, 2026. https://doi.org/10.1002/hsr2.72842 ↩
-
Sridevi Devaraj, Grant O’Keefe, Ishwarlal Jialal. Defining the Proinflammatory Phenotype Using High Sensitive C-Reactive Protein Levels as the Biomarker. The Journal of Clinical Endocrinology & Metabolism, 2005. https://doi.org/10.1210/jc.2005-0069 ↩
-
Hirokazu Honda, Abdul Rashid Qureshi, Olof Heimbürger, et al. Serum Albumin, C-Reactive Protein, Interleukin 6, and Fetuin A as Predictors of Malnutrition, Cardiovascular Disease, and Mortality in Patients With ESRD. American Journal of Kidney Diseases, 2006. https://doi.org/10.1053/j.ajkd.2005.09.014 ↩ ↩2
-
Purushothaman Ganesan. Evaluation of IL-6, CRP and hs-CRP as Early Markers of Neonatal Sepsis. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2016. https://doi.org/10.7860/jcdr/2016/19214.7764 ↩ ↩2
-
Nagwan I. Rashwan, Mohammed H. Hassan, Zeinab M. Mohey El-Deen, et al. Validity of biomarkers in screening for neonatal sepsis – A single center –hospital based study. Pediatrics & Neonatology, 2019. https://doi.org/10.1016/j.pedneo.2018.05.001 ↩
-
Jiao Li, Kangying Wang. Expression and clinical significance of WBC, hs-CRP, and ROMA index, and tumor markers in endometriosis. BMC Women’s Health, 2026. https://doi.org/10.1186/s12905-026-04749-9 ↩
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.